NEW YORK (GenomeWeb) – Shares of Exact Sciences tumbled nearly 15 percent on Wednesday as investors were spooked by a study abstract that presented data suggesting a liquid biopsy test for colorectal cancer screening could rival the performance of Exact Science's Cologuard test.

Industry analysts, however, were not convinced that the new test should be considered a competitive threat yet, and many said the dip in Exact Sciences' stock price represented a buying opportunity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.